US 12,644,104 B2Grant

Detection of environmental influences by bioluminescence

Issue Date:2026-06-02

•17 Claims

•7 Drawing Sheets

Abstract

A nucleic acid comprising a continuous nucleotide sequence, containing: (i) a gene encoding LuxA, (ii) a gene encoding LuxB, (iii) a gene encoding LuxC, (iv) a gene encoding LuxD, (v) a gene encoding LuxE, wherein each of the genes is under the control of a promoter heterologous to the respective gene, and wherein all of the genes together with the promoter are contained in a single nucleotide sequence in a row. The vectors and host cells comprise the nucleic acid. Methods of producing a host cell and methods and uses for detecting an environmental effect and a kit therefor.

Metadata

Assignee

Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen

Inventors

Jan Borlinghaus
Martin Gruhlke
Jana Foerster
Alan Slusarenko
Michael Eberhard Ries

Application Information

Application Number:US 18/028,315

Filing Date:2021-11-03

Priority Date:2020-11-04

Art Unit:1652

Classifications

IPC:

C12N9/02C12N1/16C12N9/06C12N15/52C12Q1/6897

Field of Search:

C12N 9/0069C12N 1/16

Patent Drawings (7 sheets)

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This is a National Stage application of PCT international application PCT/EP2021/080449, filed on Nov. 3, 2021, which claims the priority of German Patent Application No. 10 2020 129 009.8 filed Nov. 4, 2020, both of which are incorporated herein by reference in their entirety.

SEQUENCE LISTING

[0002] The material in the XML text file, named EISEN-67933-Sequence-Listing.txt created Mar. 8, 2023, file size of 102,400 bytes, is hereby incorporated by reference.

FIELD OF THE INVENTION

[0003] The present invention relates to a nucleic acid comprising a continuous nucleotide sequence, containing: (i) a gene encoding LuxA, (ii) a gene encoding LuxB, (iii) a gene encoding LuxC, (iv) a gene encoding LuxD, (v) a gene encoding LuxE, wherein each of the genes is under the control of a promoter heterologous to the respective gene, and wherein all of the genes together with the promoter are contained in a single nucleotide sequence in a row. The invention further relates to vectors and host cells comprising the nucleic acid. Also described are methods of producing a host cell according to the invention and methods and uses for detecting an environmental effect and a kit therefor.

BACKGROUND

[0004] Although bioluminescence has evolved in parallel several times, the basic light reaction is the same in all organisms. A luciferase catalyzes the reaction of luciferin with oxygen consumption to form a luciferase-bound peroxy-luciferin intermediate product, which releases its excess energy by emitting light. The use of luciferases such as Renilla luciferase from Renilla reniformis, Firefly luciferase from Photinus pyralis, or bacterial luciferases, e.g., from Vibrio, Photobacterium, or Photorhabdus luminescens in bioanaly-sis has been described previously (Bhaumik & Gambhir, 2002; Contag et al., 1995; Contag et al., 1998).

[0005] The bacterial luciferase is a heterodimer and is encoded by the luxA and luxB genes (Foran & Brown, 1988). The luxC, luxD, and luxE genes encode a transferase (LuxD) and a synthetase/reductase (LuxCE) that are necessary for the synthesis of the aldehyde substrate required in the light reaction. These genes are part of the bacterial lux operon (Close et al., 2009).

[0006] However, the different genetic organization of bacterial genes compared to eukaryotic genes makes direct gene transfer from bacteria to fungi or other eukaryotes difficult. Several approaches to express the bacterial system in yeast have been described in the state of the art (Gupta et al., 2003; Xu et al., 2018). For the expression of the bacterial lux system in eukaryotes, the prokaryotic operon structure was previously mimicked using specific gene-linking sequences. This was the only way to regulate all genes using only one promoter and one terminator. In both publications, the genes of the lux operon are arranged in a gene cassette one after the other, wherein the coding gene sequences are linked by IRES (internal ribosomal entry sites) or 2A sequences.

[0007] The biggest and broadest application potential of bioluminescence exists currently in the field of biosensors. By introducing a luciferase fused to a regulatory DNA sequence, which induces luciferase expression only in the presence of a specific stimulus, an inducible reporter system can be established. Such a system can be automated and used for high-throughput screening.

[0008] However, the disadvantages associated with IRES (decreasing expression of genes after each IRES sequence) or 2A sequences (retention of the 2A sequence C-terminally at the cleavage site and a proline N-terminally at the cleavage site) make the luciferase systems known from the prior art less efficient for this purpose. The task of the present invention was therefore to provide an improved luciferase system suitable for use as a biosensor.

SUMMARY OF THE INVENTION

[0009] The inventors could unexpectedly demonstrate that combining all the genes of the lux operon on a single nucleic acid, wherein each gene has its own promoter and terminator, was advantageous over the luciferase systems described in the prior art, whereby the technical problem was solved.

[0010] The present invention therefore relates to a nucleic acid comprising a continuous nucleotide sequence containing: (i) a gene encoding LuxA, (ii) a gene encoding LuxB, (iii) a gene encoding LuxC, (iv) a gene encoding LuxD, (v) a gene encoding LuxE, wherein each of the genes is under the control of a promoter heterologous to the respective gene, and wherein all genes together with the promoter are contained in a single nucleotide sequence in a row.

[0011] Preferably, the heterologous promoter is a eukaryotic promoter. Preferably, the heterologous promoters mediate approximately equal expression strength. Each gene may be followed by a terminator.

[0012] LuxA and LuxB are preferably from Photorhabdus luminescens or Vibrio harveyi, preferably P. luminescens. In the nucleic acid according to the invention, the genes encoding LuxA (i) and LuxB (ii) are preferably present as one gene luxAB encoding the LuxA/LuxB fusion protein and wherein LuxA and LuxB are preferably connected by a linker. The fusion protein or gene encoding the fusion protein is under the control of its own heterologous promoter and can thereby replace genes (i) and (ii) including their associated heterologous promoters in the nucleic acid according to the invention. LuxA preferably has an amino acid sequence that is at least 70%, at least 80%, at least 90%, at least 95%, at least 97.5%, at least 99% or 100% identical to SEQ ID NO: 1 or a functional fragment thereof. LuxB preferably has an amino acid sequence that is at least 70%, at least 80%, at least 90%, at least 95%, at least 97.5%, at least 99%, or 100% identical to SEQ ID NO: 2 or a functional fragment thereof.

[0013] LuxC, luxD and luxE are preferably from P. luminescens. LuxC preferably has an amino acid sequence that is at least 70%, at least 80%, at least 90%, at least 95%, at least 97.5%, at least 99%, or 100% identical to SEQ ID NO: 3 or a functional fragment thereof. LuxD preferably has an amino acid sequence that is at least 70%, at least 80%, at least 90%, at least 95%, at least 97.5%, at least 99%, or 100% identical to SEQ ID NO: 4 or a functional fragment thereof. LuxE preferably has an amino acid sequence that is at least 70%, at least 80%, at least 90%, at least 95%, at least 97.5%, at least 99%, or 100% identical to SEQ ID NO: 5 or a functional fragment thereof.

[0014] The nucleic acid preferably additionally comprises (vi) a gene encoding an NADPH-flavin oxidoreductase. The NADPH-flavin oxidoreductase is preferably frp, preferably from V. harveyi, wherein the NADPH-flavin oxidoreductase preferably has an amino acid sequence that is at least 70%, at least 80%, at least 90%, at least 95%, at least 97.5%, at least 99%, or 100% identical to SEQ ID NO: 6 or a functional fragment thereof.

[0015] The nucleic acid preferably does not contain an internal ribosomal entry site (IRES) and/or self-cleaving peptides, e.g., 2A peptides, between any of genes (i) to (vi).

[0016] LuxA and luxB or the LuxA/LuxB fusion protein are preferably under the control of a regulatable promoter, wherein the promoter is preferably regulatable by an environmental influence, (wherein the environmental influence) is preferably selected from the group consisting of medicaments, drugs, hormones, environmental toxins, bioavailable compounds and physical influences.

[0017] LuxC, luxD, luxE and optionally the NADPH-flavin oxidoreductase may be constitutively expressed or be under the control of an inducible promoter, wherein the promoter of luxC is preferably the TEF2 promoter, the promoter of luxD is preferably the CDCl9 promoter, the promoter of luxE is preferably the ENO2 promoter, and/or the promoter of the NADPH-flavin oxidoreductase is preferably the PDC1 promoter. In one embodiment, luxC, luxD, luxE and optionally the NADPH-flavin oxidoreductase are under the control of an inducible promoter.

[0018] The present invention further relates to a vector, e.g., a plasmid, comprising the nucleic acid of the invention.

[0019] The present invention further relates to a host cell comprising the nucleic acid according to the invention or the vector according to the invention, wherein the host cell is preferably a eukaryotic host cell. Preferably, the host cell is a yeast, preferably a yeast selected from the group consisting of Komagataella phaffii (Pichia pastoris), Hansenula polymorpha, Trichoderma reesei, Aspergillus niger, Saccharomyces cerevisiae, Kluyveromyces lactis, Yarrowia lipolytica, Pichia methanolica, Candida boidinii, Komagataella spp., Schizosaccharomyces pombe and Blastobotrys adeninivorans (also known as Arxula adeninivorans), preferably Saccharomyces cerevisiae. The nucleic acid according to the invention may be integrated into a chromosome of the host cell.

[0020] The present invention further relates to a method of producing a host cell according to the invention comprising introducing the nucleic acid according to the invention or the vector according to the invention into a host cell.

[0021] The present invention further relates to a method for detecting an environmental agent comprising: (i) contacting an environmental sample with the host cell according to the invention; (ii) determining the luminescence of the host cell; wherein luxA and luxB or the LuxA/LuxB fusion protein are under the control of a regulatable promoter that is regulated by the environmental agent and wherein a change in bioluminescence compared to a control sample is indicative of the presence of the environmental agent, wherein the environmental agent is preferably selected from the group consisting of medicaments, drugs, hormones, environmental toxins, bioavailable compounds and physical agents.

[0022] The present invention further relates to a use of a host cell according to the invention as a biosensor or in a method for detecting an environmental effect according to the invention or for detecting protein-protein interactions.

[0023] The present invention further relates to the use of a host cell according to the invention as a vitality sensor, wherein the reduction or loss of bioluminescence is indicative of reduced vitality of the host cell.

[0024] The present invention further relates to a kit comprising the nucleic acid according to the invention, the vector according to the invention, or the host cell according to the invention.

FIGURES

[0025] FIG. 1 shows the measurement of luminescence (black) and growth (gray) of S. cerevisiae strain BY4742 containing plasmid pRS426-Lux, a nucleic acid according to the invention.

[0026] FIGS. 2A, 2B, 2C, and 2D show the bioluminescence of the host cell according to the invention. FIG. 2A shows the CSM-URA plate photographed at daylight and FIG. 2B in complete darkness. FIG. 2C is a schematic representation of the invention. FIG. 2D shows a comparison of the host cell according to the invention (“prototype”, top line) with Firefly luciferase (middle line) and empty vector pRS426 (bottom line).

[0027] FIG. 3 shows a luminescence measurement of S. cerevisiae (dark line) as well as the OD600 (light line), which were transformed with plasmids pRS426-Leu2-LuxAB and pRS426-Ura3-LuxCDE-frp.

[0028] FIG. 4 shows the course of luminescence at different concentrations of leucine and controls (water, URA and histidine), respectively.

[0029] FIG. 5 shows an example of a nucleic acid according to the invention based on the pRS426 plasmid (see also SEQ ID NO: 7).

[0030] FIG. 6 shows an exemplary plasmid encoding Firefly luciferase (SEQ ID NO: 20).

[0031] FIG. 7 shows two example plasmids encoding LuxA/B (SEQ ID NO: 22) and LuxC/D/E (SEQ ID NO: 21) on two different plasmids.

DETAILED DESCRIPTION

[0032] In 2018, the research group of Xu et al. reported that they had developed a bioluminescent reporter that could detect dioxins and dioxin-like substances. For this, the lux operon and frp were placed under control of a dioxin-sensitive promoter and the individual genes were linked via different viral 2A elements to allow expression with a single promoter. The 2A peptides were used due to their small sequence size (54-174 bp) (Xu et al., 2018). However, the use of these sequences also comes with some crucial disadvantages. For example, the 2A peptide remains as a C-terminal extension on the product located upstream, and the N-terminus of the downstream product is extended to include the amino acid proline. This C-terminal extension can cause the conformation of the protein to be compromised, resulting in limited or complete loss of activity (Minskaia et al., 2013). In addition, in certain cases, the C-terminal sequence of the upstream gene can completely inhibit the cutting of the 2A peptide. This can lead to aggregation of the proteins in the organism (Minskaia et al., 2013).

[0033] Another example known from the prior art of lux operon expression in S. cerevisiae was also relied on the use of viral elements. In this work, IRES sequences were used to bicistronically express luxE and frp and luxD and luxC. LuxAB and luxCDE+frp were also each cloned onto their own vectors (Gupta et al., 2003). However, IRES sequences have even greater disadvantages compared with 2A peptides. These sequences provide an additional binding site to ribosomes and recruit ribosomes independently of elongation factors inhibited by the viruses (Pelletier & Sonenberg, 1988). However, the required binding factors differ from cell to cell. In addition, the protein encoded downstream by IRES is usually expressed only 20%-50% in contrast to the protein encoded upstream (Mizuguchi et al., 2000).

[0034] The associated drawbacks therefore prevent a widespread applicability and reliability in the use of eukaryotic cells as biosensors. The solution found by the inventors avoids the use of viral factors. The nucleic acid according to the invention differs from the prior art in that, first, all of the genes of the lux operon are encompassed on a single nucleic acid and each of the genes of the lux operon is under the control of its own promoter. Host cells comprising the nucleic acid according to the invention can be used for a variety of different purposes, which we will discuss below.

[0035] As the inventors were able to show, the system they used is surprisingly clearly superior to a system split between two nucleic acids and the Firefly luciferase (see Example 3, FIG. 2). FIG. 2D shows the comparison of the plasmids pRS426-Lux, i.e. the nucleic acid according to the invention, and pRS426-FBA1::Firefly from the prior art, which have the same regulatory elements, during growth in appropriate deficiency medium. In the case of pRS426-Lux, no luciferin was added externally, whereas luciferin had to be added in excess to the Firefly plasmid. It can be seen that the luminescence signal of Firefly luciferase decreases very rapidly as the luciferin is simply consumed. In contrast, the bacterial luciferase produces a constant signal that is also more than twice as strong (FIG. 2D). This also allows a comparison with Xu et al. who report the luminescence intensity in “fold of induction” (FOI). FOI is the ratio of the average luminescence signal at time t to a negative control, which is also referred to as background lighting. Xu et al. obtain a maximum value of 13.8 FOI. Calculating the FOI for the highest value obtained in this disclosure (FIG. 2D), one would obtain an induction of 738 FOI (130,000 RLU signal versus 176 RLU background lights). This would mean a light signal more than 50 times stronger than that obtained by Xu et al, highlighting the clear superiority of the system according to the invention. Furthermore, another advantage of the bacterial lux system according to the invention is that the substrate can be produced by the host cell itself. By eliminating the addition and purchase of luciferin, labor time and costs can be reduced.

[0036] Accordingly, the present invention relates to a nucleic acid comprising a continuous nucleotide sequence containing: (i) a gene encoding LuxA, (ii) a gene encoding LuxB, (iii) a gene encoding LuxC, (iv) a gene encoding LuxD, (v) a gene encoding LuxE, wherein each of the genes is under the control of a promoter heterologous to the respective gene, and wherein all of the genes together with the promoter are contained in a single nucleotide sequence in a row.

[0037] The nucleic acid thus contains all essential genes that enable bioluminescence. The nucleic acid is continuous, i.e. all genes are located on a single, continuous nucleic acid. In other words, they are included together with the promoter in a single nucleotide sequence in a row. However, this does not necessarily preclude the possibility of non-coding regions or genes that are not from the lux operon being located between the individual genes. Also, it does not necessarily mean that the sequence of genes (i) through (vi) as described herein must be present on the nucleic acid in the order of their numbering.

[0038] As explained earlier, the nucleic acid contains genes encoding the lux operon. The genes responsible for prokaryotic bioluminescence were isolated and characterized from Vibrio harveyi by Engebrecht et al. (1983). These are referred to within this disclosure as the “lux operon”. The genes contained in the lux operon are referred to as luxC, luxD, luxE, luxA, and luxB.

[0039] The bacterial luciferase is a heterodimer, which is formed by LuxA and LuxB (Foran and Brown, 1988). LuxA and LuxB hereby can be from Photorhabdus luminescens or Vibrio harveyi, wherein LuxA and LuxB preferably being from P. luminescens. In a preferred embodiment, LuxA has an amino acid sequence that is at least 70%, at least 80%, at least 90%, at least 95%, at least 97.5%, at least 99%, or 100% identical to SEQ ID NO: 1 or a functional fragment thereof. In a preferred embodiment, LuxB has an amino acid sequence that is at least 70%, at least 80%, at least 90%, at least 95%, at least 97.5%, at least 99%, or 100% identical to SEQ ID NO: 2 or a functional fragment thereof.

[0040] Another embodiment relates to a nucleic acid according to the present invention, wherein the genes encoding LuxA (i) and LuxB (ii) are present as a gene luxAB encoding the LuxA/LuxB fusion protein, and wherein LuxA and LuxB are preferably connected by a linker.

[0041] This means, according to this particular embodiment, LuxA and LuxB are present as a fusion protein (LuxA/LuxB fusion protein). Within the fusion protein, LuxA and LuxB may be connected by a linker, e.g. a serine-threonine linker or a serine-arginine linker, preferably a serine-arginine linker. The fusion protein or the gene encoding the fusion protein is under the control of its own heterologous promoter and can thereby replace genes (i) and (ii) including their associated heterologous promoters in the nucleic acid according to the invention. An exemplary fusion protein of LuxA and LuxB is shown in SEQ ID NO: 8. The LuxA/LuxB fusion protein may be under the control of an FBA1 promoter (as shown, for example, in SEQ ID NO: 13). Alternatively, the LuxA/LuxB fusion protein may be under the control of the OSI1 promoter (as shown, for example, in SEQ ID NO: 19). Consequently, the present invention accordingly also relates to a nucleic acid comprising a continuous nucleotide sequence containing: (i) a gene encoding a LuxA/LuxB fusion protein, (iii) a gene encoding LuxC, (iv) a gene encoding LuxD, (v) a gene encoding LuxE, wherein each of the genes is under the control of a promoter heterologous to the respective gene, and wherein all of the genes together with the promoter are contained in a single nucleotide sequence in a row.

[0042] The remaining genes of the lux operon luxC, luxD, and luxE are coding for a transferase (LuxD) and for a synthetase/reductase (LuxCE), which ensure that the aldehyde substrate required for the light reaction is present in a sufficient amount (Close et al., 2009). The aldehyde substrate for the bacterial luciferase is also referred to as bacterial luciferin in this context. The Lux operon is also the basis for other bioluminescent bacteria such as Photobacterium phosphoreum (Dunlap, 2014). LuxC, LuxD, and LuxE are preferably from P. luminescens. In a preferred embodiment, LuxC has an amino acid sequence that is at least 70%, at least 80%, at least 90%, at least 95%, at least 97.5%, at least 99%, or 100% identical to SEQ ID NO: 3 or a functional fragment thereof. In a preferred embodiment, LuxD has an amino acid sequence that is at least 70%, at least 80%, at least 90%, at least 95%, at least 97.5%, at least 99%, or 100% identical to SEQ ID NO: 4 or a functional fragment thereof. In a preferred embodiment, LuxE has an amino acid sequence that is at least 70%, at least 80%, at least 90%, at least 95%, at least 97.5%, at least 99%, or 100% identical to SEQ ID NO: 5 or a functional fragment thereof.

[0043] To support luciferin synthesis in the context of the invention, a NAPDH-flavin oxidoreductase may additionally be overexpressed or additionally expressed. This may be comprised on an additional nucleic acid or on the nucleic acid according to the invention. Preferably, the nucleic acid according to the invention (vi) comprises a gene encoding an NADPH-flavin oxidoreductase. Preferably, the NADPH-flavin oxidoreductase is frp, preferably frp from Vibrio harveyi. In a special embodiment, the NADPH-flavin oxidoreductase has an amino acid sequence that is at least 70%, at least 80%, at least 90%, at least 95%, at least 97.5%, at least 99% or 100% identical to SEQ ID NO: 6 or a functional fragment thereof.

[0044] A “functional fragment” in the context of the present invention means a fragment of each protein that has an activity of at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95% of the unmodified protein, i.e., the sequence recited in the present disclosure. Determining the activity of a protein is within the capabilities of the skilled person. For this purpose, the activity, e.g., luminescence, between the respective reference sequence and the fragment to be tested can be compared under otherwise identical conditions.

[0045] Sequence identity can be determined by any known method, but computer programs are useful for determining the degree of identity of sequences. Multiple sequence alignment and % identity calculations can be performed using standard BLAST parameters (use sequences from all available organisms, matrix BLOSUM 62, gap costs: existence 11, extension1). Alternatively, the program Align Plus 4, version 4.10 (Sci Ed Central Clone Manager Professional Suite) can be used with the following parameters: DNA comparison: Global comparison, Standard Linear Scoring Matrix, Mismatch Penalty=2, Open Gap Penalty=4, Extend Gap Penalty=1/Amino Acid Comparison: Global Comparison, BLOSUM 62 Scoring Matrix.

[0046] “Nucleic acid” as used herein describes macromolecules built from individual building blocks, the nucleotides, which in all organisms contain the genetic information. Alternating single sugars and phosphoric acid esters form a chain, wherein a nucleic base is attached to each sugar. The nucleic acid can be DNA or RNA, wherein DNA is preferred. When a nucleic acid is expressed, it leads to the production of the peptide or protein encoded by the respective gene.

[0047] In the nucleic acid according to the invention, each of the genes is under the control of an (own) promoter heterologous to the respective gene. The respective heterologous promoter is preferably a eukaryotic promoter. The promoters of the individual genes (i) to (v) or (i) to (vi) may be the same, but are preferably different. Preferably at least one promoter is different compared to the other promoters used, more preferably at least two promoters are different compared to the other promoters, wherein also the two promoters are different compared to each other, even more preferably at least three promoters are different compared to the other promoters, wherein also the three promoters are different compared to each other, most preferably all promoters used are different compared to each other. The term eukaryotic promoter may include synthetic promoters. The term eukaryotic promoter may include the cauliflower mosaic virus 35S promoter or other viral promoters.

[0048] Since the genes of the lux operon are equivalently expressed in bacteria, an attempt can be made to mimic this by using promoters of equal strength in eukaryotes. However, this is not essential for the feasibility of the invention. Therefore, the heterologous promoters preferably mediate equal expression strength. “Expression strength” in this context means the amount (e.g., number) of mRNA transcribed and/or the amount (e.g., mass) of proteins translated. “Equal” in this context may include a deviation of 25% or less, 10% or less, or 5% or less. Methods for determining the amount of mRNA and proteins are well known to those skilled in the art and are described, for example, in Sun et al. (2012), Biotechnology and Bioengineering 2012, 109:2082-2092. For example, quantitative PCR can be used to compare the transcribed amount of mRNA of the same gene, e.g., gfp, as a function of different promoters. Alternatively or additionally, a gene encoding a fluorescent protein such as GFP can be placed under the control of different promoters and the respective fluorescence determined as a function of the promoter.

[0049] The bioluminescence mediated by the expression products of the nucleic acid according to the invention can be used to detect a wide variety of factors, e.g. environmental influence. For this purpose, luxA and luxB or the LuxA/LuxB fusion protein are preferably under the control of a regulatable promoter. “Regulatable” in this context may mean induction of gene expression or repression of gene expression in response to an environmental influence. Thus, the regulatable promoter is preferably regulatable by an environmental influence.

[0050] In the context of the invention, it is advantageous if luxC, luxD, luxE and optionally the NADPH oxidoreductase are already expressed before the expression of the luciferase luxA/luxB. This has the advantage that the substrate luciferin can already be available in the host cell before the expression of the luciferase luxA/luxB is started. This may allow for a faster availability of bioluminescence, since the proteins that produce the substrate of luciferase do not have to be additionally expressed first. Accordingly, luxC, luxD, luxE, and optionally NADPH-flavin oxidoreductase may be constitutively expressed or under the control of a regulatable promoter. In one embodiment, luxC, luxD, luxE and optionally the NADPH-flavin oxidoreductase are under the control of an inducible promoter. In the case of a regulatable or inducible promoter, the promoters of luxC, luxD, luxE and optionally the NADPH-flavin oxidoreductase are preferably different from the (inducible) promoters of luxA and luxB. The promoter of luxC is preferably the TEF2 promoter (e.g. as shown in SEQ ID NO: 9), the promoter of luxD is preferably the CDC19 promoter (e.g. as shown in SEQ ID NO: 10), the promoter of luxE is preferably the ENO2 promoter (e.g. as shown in SEQ ID NO: 11) and/or the promoter of NADPH-flavin oxidoreductase is preferably the PDC1 promoter (e.g. as shown in SEQ ID NO: 12).

[0051] Each of genes (i) to (v) or (i) to (vi) may be followed by a terminator. A “terminator” or “transcription terminator” may refer to a segment of genetic sequence on DNA that marks the end of a gene or operon as it leads to the termination (termination) of transcription. Examples of terminators include, but are not limited to, the TEF2 terminator (as shown in SEQ ID NO: 14), the CDC19 terminator (as shown in SEQ ID NO: 15), the ENO2 terminator (as shown in SEQ ID NO: 16), the PDC1 terminator (as shown in SEQ ID NO: 17), or the FBA1 terminator (as shown in SEQ ID NO: 18).

[0052] As explained above, it is an advantage of the present invention that the nucleic acid according to the invention does not need to contain an IRES sequence or 2A peptide sequence. In cell biology, an internal ribosomal entry site, abbreviated IRES, is a specifically folded portion of the secondary structure of an RNA single strand that mediates binding to ribosomes. This allows translation to be initiated in the synthesis of proteins in eukaryotes independently of the 5′-cap structure, for example, even starting from the middle of a messenger RNA (mRNA). IRES have previously been found in the RNA of viruses as well as described in the mRNA for some genes of cells. 2A-self-cleaving peptides or 2A-peptides form a class of 18-22 amino acid long peptides that can induce cleavage of a recombinant protein in a host cell. For example, 2A peptides are derived from the 2A region of foot-and-mouth disease virus. In one embodiment, the nucleic acid of the invention does not contain an IRES sequence and/or a 2A peptide sequence between any of genes (i) to (vi).

[0053] The present invention further relates to a vector comprising the nucleic acid according to the invention. A “vector” or also “plasmid” refers to a nucleic acid that is suitable as a transport vehicle for transferring a foreign nucleic acid (e.g., DNA) into a (living) host cell by transfection or transduction. Exemplary for this purpose can be mentioned the pRS426 plasmid, which is described e.g. in (Mumberg et al., 1995) et al. The vector preferably contains one or more replication origins that allow for propagation or persistence in a host cell. These can be adapted by the skilled person depending on the intended host cell. A vector according to the invention is exemplified in SEQ ID NO: 7.

[0054] Methods for producing the nucleic acid or vector according to the invention are sufficiently known to those skilled in the art. In addition to cloning the individual genes into a nucleic acid or vector, the nucleic acid or vector may alternatively be produced by total synthesis. The genes may be codon-optimized depending on the host cell.

[0055] The present invention further relates to a host cell comprising the nucleic acid according to the invention or the vector according to the invention. Preferably, the host cell is a eukaryotic host cell. Especially preferably, the host cell is a yeast, wherein the yeast is preferably selected from the group consisting of Komagataella phaffii (Pichia pastoris), Hansenula polymorpha, Trichoderma reesei, Aspergillus niger, Saccharomyces cerevisiae, Kluyveromyces lactis, Yarrowia lipolytica, Pichia methanolica, Candida boidinii, Komagataella spp., Schizosaccharomyces pombe, and Blastobotrys adeninivorans (also known as Arxula adeninivorans). In a particularly preferred embodiment according to the invention, the host cell is Saccharomyces cerevisiae. In a particular embodiment, the host cell is S. cerevisiae strain BY4742, as described, for example, in Brachmann et al. 1998. The nucleic acid or vector according to the invention may be integrated into a chromosome of the host cell.

[0056] The present invention further relates to a method of producing a host cell according to the invention comprising introducing the nucleic acid according to the invention or the vector according to the invention into a host cell. Methods for introducing nucleic acids or vectors into a host cell are well known to those skilled in the art. For example, the host cell may be transformed or transduced with the nucleic acid or vector according to the invention.

[0057] The nucleic acid, the vector, or the host cell according to the invention can be used for a variety of purposes. One such purpose is to detect an environmental influence. In the context of using a regulatable promoter to control luxA and luxB or the LuxA/LuxB fusion protein, the change in bioluminescence can be observed and used to infer the presence or absence of the environmental influence. The strength of the luminescence can also be used for concentration determination (see also Example 4). Consequently, the present invention also relates to a method for detecting an environmental influence, comprising: (i) contacting an environmental sample with the host cell according to the invention; (ii) determining the luminescence of the host cell; wherein luxA and luxB or the LuxA/LuxB fusion protein are optionally under the control of a regulatable promoter that is activated or influenced by the environmental influence and wherein an increase in bioluminescence compared to a control sample is indicative of the presence of the environmental influence (in the context of an inducible promoter) or wherein a decrease in bioluminescence compared to a control sample is indicative of the presence of the environmental influence (when using a repressible promoter). Such a method for detecting an environmental influence may be the basis for using the host cell as an environmental sensor. Preferably, no substrate for LuxA/LuxB luciferase is added externally to the host cell. In one embodiment, luxA and luxB or the LuxA/LuxB fusion protein are not under the control of a regulatable promotor, but under the control of a constitutive promoter. In this case, if the environmental influence alters (strengthen or weaken) the growth of the host cell, the change in bioluminescence can be used to detect the environmental influence. Consequently, the present invention also relates to a method for detecting an environmental influence comprising: (i) contacting an environmental sample with the host cell according to the invention; (ii) determining the luminescence of the host cell; wherein luxA and luxB or the LuxA/LuxB fusion are optionally under the control of a constitutive promoter, and wherein a change in bioluminescence compared to a control sample is indicative of the presence of the environmental influence.

[0058] An “environmental influence” in the context of the present disclosure means any influence that is capable of altering gene expression of a gene under the control of a regulatable promoter, and/or is lethal or growth inhibitory to the host cell. This can be in terms of an analyte, a synthetic or natural compound, bioavailable compound (such as nutrients, amino acids, nucleic acids, nitrogen, phosphorus, sulfur), a physical influence that can act directly or indirectly (indirect meaning, for example, when an analyte activates a signaling pathway that ultimately acts on the regulatory element) on the regulatory element. Thus, the system can be used as an indicator of environmental influences, as well as for gene expression and regulation, and monitoring of bioavailable compounds, as bioluminescence is altered/regulated in response to metabolism (protein synthesis, DNA synthesis) or growth. Examples of environmental influences include medicaments, drugs, hormones, environmental toxins, bioavailable compounds, and physical influences.

[0059] “Medicaments” may include substances and preparations used in humans or animals and intended to cure, alleviate, or prevent disease or pathological conditions, or to restore, correct, or influence physiological functions. They can also serve as a basis for medical diagnoses. The environmental influence can be an antibiotic.

[0060] “Drugs” may include the following: benzodiazepines, thienodiazepines, indole alkaloids (e.g., LSD), opioids (e.g., morphine, diacetylmorphine, methadone), arylcyclohexylamines (e.g., ketamine), phenylethylamines (e.g., amphetamines), tropane alkaloids (e.g., cocaine, scopolamine), xanthines, or cannibinoids (e.g., cannabidiol, THC).

[0061] “Hormones” can be endogenous or non-endogenous, but hormone-like substances. Examples are estrogens, gestagens, but also substances that have hormone-like effects such as DDT, PCB, PBDE or phthalates.

[0062] As “environmental toxins” can be understood substances or preparations which themselves or their transformation products are capable of changing the condition of the natural balance, water, soil or air, climate, animals, plants or microorganisms in such a way that hazards to the environment can be brought about immediately or later. Environmental toxins can be chemical substances that are classified as “environmentally hazardous” under the GHS labeling. Examples include dichlorodiphenyltrichloroethane (DDT), volatile halogenated hydrocarbons (VHHs such as dichloromethane, trichloromethane, trichloroethane), pentachlorophenol (PCP), polybrominated diphenyl ethers (PBDEs), polychlorinated biphenyls (PCBs), polychlorinated dibenzodioxins and dibenzofurans, polycyclic aromatic hydrocarbons (PAHs such as. e.g. benzo[a]pyrene), propenal, sulfur trioxide, heavy metals (e.g. arsenic, antimony, lead, cadmium, chromium, copper, nickel, thallium, mercury) or TMDD.

[0063] A “bioavailable compound” can be understood as a substance or mixture of substances that can be metabolized by organisms without harming them. Examples include nutrients, nitrogen and nitrogen compounds, phosphorus and phosphorus compounds, and sulfur and sulfur compounds.

[0064] A “physical influence” may refer to an environmental influence that can affect a host cell via parameters such as heat, cold, or osmotic concentration. Another physical influence may be oxidative stress. To detect oxidative stress, the OSI1 promoter can be used to control the expression of luxA/luxB.

[0065] An “environmental sample” may refer to a sample obtained from the environment, i.e., not from an animal, for example. Exemplary environmental samples are water samples (e.g., sea, lakes, streams, wastewater, drinking water) or soil samples, preferably water samples.

[0066] Methods for measuring bioluminescence are sufficiently known to the skilled person. They include, for example, the use of a photometer e.g. within a (micro) plate reader. The basis of these methods is the measurement of light emitted by the host cell. The activity of the bacterial LuxA/LuxB luciferase described in this disclosure can be measured at about 490 nm.

[0067] As mentioned herein, the host cell according to the invention can be used as a biosensor. Consequently, the invention also relates to the use of the host cell as a biosensor. “Biosensor” in the context of the invention may refer to the use of the host cell according to the invention to detect an environmental effect, e.g., in a method of detecting an environmental effect as described herein. Preferably, no substrate for LuxA/LuxB luciferase is added externally to the host cell.

[0068] The host cell according to the invention can additionally be used as a vitality sensor. In an exemplary embodiment, luxA and luxB or the LuxA/LuxB fusion protein are under the control of a constitutively active promoter. That is, the luminescence of the host cell remains constant. If the vitality of the host cell decreases, e.g., due to the influence of an environmental toxin, the host cell may restrict the protein production or die, causing the luminescence to decrease. That is, the level of luminescence may serve as an indicator of the vitality of the host cell. Consequently, the present invention relates to the use of the host cell according to the invention as a vitality sensor, wherein the decrease or loss of (bio)luminescence is indicative of decreased vitality of the host cell. Preferably, no substrate for LuxA/LuxB luciferase is added externally to the host cell.

[0069] The nucleic acid according to the invention may also be used to detect protein-protein interactions. For this purpose, a system similar to a yeast two-hybrid system (Y2H) may be used. In an exemplary embodiment, the substrate for the LuxA/LuxB luciferase can be produced by the genes luxC, luxD, luxE and optionally NAPDH-flavin oxidoreductase, which are under the control of a constitutive promoter. At the same time, the luxA/luxB genes or the LuxA/LuxB fusion protein are under the control of a promoter activated by the binding of the reconstituted transcription factor in the Y2H system. A GaI4 promoter is often used for this purpose, which is activated by the reconstituted GaI4 transcription factor in the presence of protein-protein interaction. A luciferase-based system is described in Massoud et al. 2007.

[0070] Preferably, no substrate for LuxA/LuxB luciferase is added externally to the host cell.

[0071] The present invention further relates to a kit comprising the nucleic acid according to the invention, the vector according to the invention, or the host cell according to the invention. The kit may additionally comprise instructions. Other components may include sample collection containers, culture media, or means for transfecting the nucleic acid.

[0072] The present invention also relates to the following objects:

[0073] Nucleic acid comprising a continuous nucleotide sequence containing:

- [0074] a gene encoding LuxA,
- [0075] (ii) a gene encoding LuxB,
- [0076] (iii) a gene encoding LuxC,
- [0077] (iv) a gene encoding LuxD,
- [0078] (v) a gene encoding LuxE,

[0079] wherein each of the genes is under the control of a promoter heterologous to the respective gene, and wherein all of the genes together with the promoter are contained in a single nucleotide sequence in a row.

[0080] 2. Nucleic acid according to object 1, wherein the heterologous promoter is a eukaryotic promoter.

[0081] 3. Nucleic acid according to object 1 or 2, wherein the heterologous promoters mediate approximately equal expression levels.

[0082] 4. Nucleic acid according to any of the preceding objects, wherein each gene is followed by a terminator.

[0083] 5. Nucleic acid according to any of the preceding objects, wherein LuxA and LuxB are from Photorhabdus luminescens or Vibrio harveyi, preferably P. luminescens.

[0084] 6. Nucleic acid according to any one of the preceding objects, wherein the genes encoding LuxA (i) and LuxB (ii) are present as a gene luxAB encoding the LuxA/LuxB fusion protein, and wherein LuxA and LuxB are preferably connected by a linker.

[0085] 7. Nucleic acid of any one of the preceding objects, wherein LuxA has an amino acid sequence that is at least 70%, at least 80%, at least 90%, at least 95%, at least 97.5%, at least 99%, or 100% identical to SEQ ID NO: 1 or a functional fragment thereof.

[0086] 8. Nucleic acid of any one of the preceding objects, wherein LuxB has an amino acid sequence that is at least 70%, at least 80%, at least 90%, at least 95%, at least 97.5%, at least 99%, or 100% identical to SEQ ID NO: 2 or a functional fragment thereof.

[0087] 9. Nucleic acid according to any one of the preceding items, wherein LuxC, LuxD and LuxE are from P. luminescens.

[0088] 10. Nucleic acid of any one of the preceding objects, wherein LuxC has an amino acid sequence that is at least 70%, at least 80%, at least 90%, at least 95%, at least 97.5%, at least 99%, or 100% identical to SEQ ID NO: 3 or a functional fragment thereof.

[0089] 11. Nucleic acid of any one of the preceding objects, wherein LuxD has an amino acid sequence that is at least 70%, at least 80%, at least 90%, at least 95%, at least 97.5%, at least 99%, or 100% identical to SEQ ID NO: 4 or a functional fragment thereof.

[0090] 12. Nucleic acid of any one of the preceding objects, wherein LuxE has an amino acid sequence that is at least 70%, at least 80%, at least 90%, at least 95%, at least 97.5%, at least 99%, or 100% identical to SEQ ID NO: 5 or a functional fragment thereof.

[0091] 13. Nucleic acid according to any one of the preceding objects, wherein the nucleic acid additionally comprises (vi) a gene encoding an NADPH-flavin oxidoreductase.

[0092] 14. Nucleic acid of object 13, wherein the NADPH-flavin oxidoreductase is frp, preferably from V. harveyi, wherein the NADPH-flavin oxidoreductase preferably has an amino acid sequence that is at least 70%, at least 80%, at least 90%, at least 95%, at least 97.5%, at least 99%, or 100% identical to SEQ ID NO: 6 or a functional fragment thereof.

[0093] 15. Nucleic acid according to any one of the preceding objects, wherein the nucleic acid does not contain an internal ribosomal entry site (IRES) and/or does not contain self-cutting peptides, e.g. 2A peptides, between any of genes (i) to (vi).

[0094] 16. Nucleic acid according to any one of the preceding objects, wherein luxA and luxB or the luxA/LuxB fusion protein are under the control of a regulatable promoter, wherein the promoter is preferably regulatable by an environmental influence, preferably selected from the group consisting of medicaments, drugs, hormones, environmental toxins, bioavailable compounds and physical influences.

[0095] 17. Nucleic acid according to any one of the preceding objects, wherein luxC, luxD, luxE and optionally the NADPH flavin oxidoreductase are constitutively expressed or under the control of a regulatable promoter, wherein the promoter of luxC is preferably the TEF2 promoter, the promoter of luxD is preferably the CDC19 promoter, the promoter of luxE is preferably the ENO2 promoter, and/or the promoter of NADPH-flavin oxidoreductase is preferably the PDC1 promoter.

[0096] 18. Vector, e.g. a plasmid, comprising the nucleic acid of any one of objects 1 to 17.

[0097] 19. Host cell comprising the nucleic acid of any one of objects 1 to 17 or the vector of object 18, wherein the host cell is preferably a eukaryotic host cell.

[0098] 20. Host cell according to object 19, wherein the host cell is a yeast, preferably a yeast selected from the group consisting of Komagataella phaffii (Pichia pastoris), Hansenula polymorpha, Trichoderma reesei, Aspergillus niger, Saccharomyces cerevisiae, Kluyveromyces lactis, Yarrowia lipolytica, Pichia methanolica, Candida boidinii, Komagataella spp., Schizosaccharomyces pombe and Blastobotrys adeninivorans, preferably Saccharomyces cerevisiae.

[0099] 21. Method of making a host cell according to object 19 or 20 comprising introducing the nucleic acid according to any one of articles 1 to 17 or the vector according to article 18 into a host cell.

[0100] 22. Method for detecting an environmental effect, comprising:

[0101] Contacting an environmental sample with the host cell according to object 19 or 20;

- [0102] (ii) Determining the luminescence of the host cell;

[0103] wherein luxA and luxB or the luxA/LuxB fusion protein are optionally under the control of a regulatable promoter that is regulated by the environmental influence and wherein a change in bioluminescence compared to a control sample is indicative of the presence of the environmental influence.

[0104] 23. Method according to object 22, wherein the environmental influence is selected from the group consisting of medicaments, drugs, hormones, environmental toxins, bioavailable compounds, and physical influences.

[0105] 24. Use of a host cell according to objects 19 or 20 as a biosensor, in a method according to subject matter 22 or 23, or for detecting protein-protein interactions.

[0106] 25. Use of a host cell according to any one of objects 19 or 20 as a vitality sensor, wherein the reduction or loss of bioluminescence is indicative of reduced vitality of the host cell.

[0107] 26. Kit comprising the nucleic acid according to any one of objects 1 to 17, the vector according to object 18, or the host cell according to object 19 or 20.

[0108] We note that the singular forms “a”, and the” used herein include plural references unless the context clearly indicates otherwise. For example, reference to “a reagent” includes one or more such different reagents, and reference to “the method” includes reference to equivalent steps and methods known to those skilled in the art that could modify or replace the methods described herein.

[0109] Unless otherwise indicated, the term “at least” before a series of elements should be understood to refer to each element in the series. Those skilled in the art may recognize or be able to find through routine experimentation many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the present invention.

[0110] The term “and/or” includes the meanings of “and”, “or”, and “all or any other combination of the elements connected by this term”.

[0111] The term “less than” or, conversely, “more than” does not include the specific number specified. For example, “less than 20” means less than the specified number. Similarly, “more than” or “greater than” means the specified number, e.g. “more than 80%” means more than or greater than the specified number of 80%.

[0112] In this description and in the following claims, unless the context indicates otherwise, the word “including” and variations such as “include” are understood to mean the inclusion of a specified integer or steps or group of integers or steps, but not the exclusion of any other integer or step or group of integers or steps. When used herein, the term “includes” may be substituted for the term “contains” or “includes” or sometimes, when used herein, for the term “has”. When used herein, “consisting of” excludes any element, step, or ingredient not specified.

[0113] The term “including” means “including but not limited to”. The terms “including” and “including but not limited to” are used interchangeably.

[0114] It should be understood that the present invention is not limited to the particular methodology, protocols, material, reagents and substances, etc., described herein and as such may vary. The terminology used herein is for the purpose of describing specific embodiments only and is not intended to limit the scope of the present invention, which is defined solely by the claims.

[0115] All publications cited throughout the text of this description (including all patents, patent applications, scientific publications, instructions, etc.), whether cited before or after, are hereby incorporated by reference in their entirety. Nothing herein shall be construed as an admission that the invention is not entitled to such prior disclosure by virtue of any prior invention. To the extent that the disclosure incorporated by reference contradicts or is inconsistent with this description, the description supersedes any such disclosure.

[0116] The following examples, which are provided for illustrative purposes only, are intended to aid in understanding the present invention and its advantages. The examples are not intended to limit the scope of the present invention in any way.

EXAMPLES

Materials and Methods

Yeast and Bacteria Strains

[0117] In this work, Saccharomyces cerevisiae strain BY4742 (genotype: MATα his3 Δ1 leu2 Δ0 lys2Δ0 ura3 Δ0) was used, which originated from the gene knockout collection of Euroscarf in Oberursel, Germany (Ando & Suzuki, 2005; Brachmann et al., 1998).

Media Used

YPD (for S. cerevisiae)

[0118]


	Components	Final concentration

	Peptone	20 g/L
	D-glucose	20 g/L
	Yeast extract	10 g/L
	Agar (for solid medium)	15 g/L

SD-URA Medium (for S. cerevisiae)

[0119]


Components	Final concentration


D-glucose	20	g/L
Ammonium sulfate	5	g/L
Yeast Nitrogen Base	1.7	g/L
CSM -URA	0.77	g/L
Agar (for solid medium)	15	g/L

SD-Leu Medium (for S. cerevisiae)

[0120]


Components	Final concentration


D-glucose	20	g/L
Ammonium sulfate	5	g/L
Yeast Nitrogen Base	1.7	g/L
CSM -Leu	0.69	g/L
Agar (for solid medium)	15	g/L

SD-Leu-URA Medium (for S. cerevisiae)

[0121]


Components	Final concentration


D-glucose	20	g/L
Ammonium sulfate	5	g/L
Yeast Nitrogen Base	1.7	g/L
CSM-Leu-URA	0.67	g/L
Agar (for solid medium)	15	g/L

Plasmids

[0122]


Name	Property	Reference

pRS426	High-copy plasmid containing f1 ori,	(Mumberg et al.,
	ColE1, beta-lactamase sequence	1995).
	and URA3 sequence.
pGADT7 AD	yeast two-hybrid “prey” plasmid for	(Chien et al.,
	the expression of proteins associated	1991)
	with the GAL4 domain.

Transformation of Yeasts

[0123] Transformation is based on the protocol of Gietz and Woods (2002) and on Jansen et al. (2005) with some modifications: Yeasts were incubated on YPD agar plates overnight for 1-2 days at 28° C. Cell layers corresponding to a 1-μl inoculation loop were added to 50 μl of previously boiled and then cooled herring sperm (2 mg/ml in 10 mM TRIS-HCl, 1 mM Na2 EDTA, pH 8) and mixed. Then, first the DNA to be transformed—and a mixture of 240 μl of 50% polyethylene glycol 6000 (weight/volume) and 36 μl of 1 M lithium acetate were added. After incubation at 30° C. for 30 minutes, heat shock was performed at 42° C. for 30 minutes. Cells were then pelleted at 3000×g for 10 minutes at room temperature. The supernatant was discarded and the cell pellet was taken up in 100 μl of distilled and sterilized water and spread on selection medium with appropriate selection. These plates were incubated at 28° C. until transformants appeared.

Luminescence Measurement

[0124] D-Luciferin sodium salt (Carl Roth, Germany) was dissolved in 0.1 M Na2 HPO4-citrate buffer pH 5 to a final luciferin concentration of 1 mM. 100 μl of an overnight yeast culture was adjusted depending on the experimental question to a suitable starting OD600 of around 1.0 or less in CSM medium. 100 μl of yeast cells, 25 μl of a test solution (e.g., amino acid), and 25 μl of 1 mM luciferin solution were added in this order to a well of a black 96-well microtiter plate with a transparent bottom (Microplate, 96 well, PS, F-Bottom (Chimney Well) μClear®, Black, Med. Binding; Greiner bio-one, Germany) for a measurement. Measurements were performed using a Tristar2S Platereader (Berthold, Germany) at a constant temperature of 28° C.

Example 1: Transformation of Plasmid pRS426-Lux into BY4742 and Growth and Luminescence Comparison Measurement

[0125] Plasmid pRS426-Lux (SEQ ID NO: 7, see also FIG. 5) was chemically transformed into S. cerevisiae strain BY4742. After two days, 86 colonies were obtained. After the colonies were separated on CSM-Ura selection plates, luminescence was successfully measured (FIG. 1). FIG. 1 shows strain BY4742 starting at a luminescence of about 3000 RLU, increasing to a maximum of 5000 RLU. Thus, the nucleic acid according to the invention can generate bioluminescence in yeast without the addition of external luciferase substrate.

Example 2: Comparison of the Bacterial Luciferase According to the Invention with the Firefly Luciferase

[0126] To compare the generated construct according to the invention pRS426-Lux (SEQ ID NO: 7) in terms of growth behavior and luminescence, a luciferase was placed under the same promoter and terminator as the bacterial luciferase LuxAB (SEQ ID NO: 20) to establish comparable conditions. The luciferase from Photinus pyralis was chosen for comparison because it is most commonly used in bioanalysis (see FIG. 6).

[0127] After both plasmids have the same genetic requirements, such as FBA1 promoter and terminator, the same vector backbone and were also transformed into BY4742, both plasmids could be directly compared. The experiment was performed twice with three technical replicates each time. The cultures were grown overnight at 28° C. and were each diluted with 50 μl of fresh medium (YPD medium). For the produced prototype (nucleic acid according to the invention, SEQ ID NO: 7), water was added instead of 50 μl of the luciferin solution (2 mM final concentration).

[0128] The nucleic acid according to the invention (“prototype”) shows an initial luminescence of about 100,000 RLU and slowly rises to 130,000 RLU after 5.4 h. The luminescence of the Firefly luciferase is about 100,000 RLU. In contrast, the Firefly luciferase starts at only 52,475 RLU and decreases to 19,143 RLU after only 1.7 h. The luminescence of the Firefly luciferase is very low. After 5.4 h, only a low luminescence of 6893 can be measured (see FIG. 2D). The CSM-URA plates were photographed in daylight (FIG. 2A) and in complete darkness (FIG. 2B) by a commercial photographic camera. The naked eye was also able to perceive the light produced by the yeasts.

[0129] Based on these data, it is clear that the nucleic acid of the present invention is far superior to conventional Firefly luciferase.

Example 3: Construction of a Biosensor Based on Lux Bioluminescence Plasmids

[0130] A plasmid was cloned, which constitutively expresses luciferase. Thus, the luminescence of the plasmid pRS426-Lux (SEQ ID NO: 7), which combines luciferin and luciferase synthesis on a single plasmid (FIG. 5), was to be compared with a system based on the two plasmids pRS426-Leu2-FBA1::LuxAB (SEQ ID NO: 22) and pRS426-URA3-LuxCDE-frp (SEQ ID NO: 21, FIG. 7). After the transformed yeasts were grown overnight, luminescence could be measured. 100 μl of the yeast culture and 50 μl of fresh culture medium were added to a measurement well (FIG. 3).

[0131] Contrary to the expectations, it was surprisingly shown that splitting the luciferin and luciferase synthesis between two plasmids did not result in higher luminescence. On the contrary—a significantly lower luminescence was measured here (FIG. 3) in contrast to the nucleic acid pRS426-Lux according to the invention. In the system based on two plasmids, the luminescence peaked after 5.3 h at only 1948 RLU.

[0132] Thus, the inventors were completely surprised to find that splitting into two plasmids had no positive effect on luminescence, but on the contrary, that expression of the lux operon from one nucleic acid according to the invention was beneficial.

Example 4: Detection of Leucine Using the System According to the Invention

[0133] There are many possibilities to use the luciferase system of the invention as a biosensor. As an example, this will be demonstrated by detecting the leucine concentration in a leucine deficiency medium.

[0134] The yeast strain BY4742 used by the inventors has several auxotrophies, including leucine auxotrophy, which makes this strain useful for leucine detection. For this purpose, the strain was grown overnight in CSM-URA medium. Since the vector pRS426-Lux (SEQ ID NO: 7, see also FIG. 5) contains a URA3 marker, normal growth is possible for these yeast cells. The next day, the cells were centrifuged and included in CSM-Leu-URA medium, i.e., medium without leucine. Consequently, these cells could not grow due to absence of the amino acid leucine. After 5 h of incubation, a defined amount of leucine was added and luminescence was subsequently measured (FIG. 4). However, it was observed that from a leucine concentration >49 mg/L, the organisms grow and the light signal increases regardless of the concentration. However, if less than 20 mg/L leucine is added, this amount has a limiting effect on cell metabolism, and thus on the maximum possible bioluminescence. By consuming the available leucine, it becomes more and more limited, causing cell metabolism and thus bioluminescence to decrease over time (FIG. 4). The relationship between available leucine and measured bioluminescence behaves in a concentration-dependent manner within a certain concentration range, so that the leucine concentration can be correlated and measured with the bioluminescence.

[0135] The nucleic acid according to the invention can thus be used with the aid of a host cell (according to the invention) to detect and quantify environmental influences such as leucine.

REFERENCES

- [0136] Ando, A., & Suzuki, C. (2005). Cooperative function of the CHD5-like protein Mdm39p with a P-type ATPase Spf1p in the maintenance of ER homeostasis in Saccharomyces cerevisiae. Molecular Genetics and Genomics, 273(6), 497-506. https://doi.org/10.1007/s00438-005-1153-6
- [0137] Bhaumik, S., & Gambhir, S. S. (2002). Optical imaging of Renilla luciferase reporter gene expression in living mice. Proceedings of the National Academy of Sciences of the United States of America, 99(1), 377-82. https://doi.org/10.1073/pnas.012611099
- [0138] Brachmann, C. B., Davies, A., Cost, G. J., Caputo, E., Li, J., Hieter, P., & Boeke, J. D. (1998). Designer deletion strains derived from Saccharomyces cerevisiae S288C: A useful set of strains and plasmids for PCR-mediated gene disruption and other applications. Yeast, 14(2), 115-132. https://doi.org/10.1002/(SICI)1097-0061(19980130)14:2<115::AID-YEA204>3.0.CO;2-2
- [0139] Chien, C. T., Bartel, P. L., Sternglanz, R., & Fields, S. (1991). The two-hybrid system: a method to identify and clone genes for proteins that interact with a protein of interest. Proceedings of the National Academy of Sciences, 88(21), 9578-9582. https://doi.org/10.1073/pnas.88.21.9578
- [0140] Close, D. M., Ripp, S., & Sayler, G. S. (2009). Reporter proteins in whole-cell optical bioreporter detection systems, biosensor integrations, and biosensing applications. Sensors, 9(11), 9147-9174. https://doi.org/10.3390/s91109147
- [0141] Contag, C. H., Contag, P. R., Mullins, J. I., Spilman, S. D., Stevenson, D. K., & Benaron, D. A. (1995). Photonic detection of bacterial pathogens in living host cells. Molecular Microbiology, 18, 593-603.
- [0142] Contag, P. R., Olomu, I. N., Stevenson, D. K., & Contag, C. H. (1998). Bioluminescent indicators in living mammals. Nature Medicine, 4(2), 245-247.
- [0143] Dunlap P. 2014. Biochemistry and Genetics of Bacterial Bioluminescence. In Bioluminescence: Fundamentals and Applications in Biotechnology-Volume 1, pp. 37-64, Springer-Verlag Berlin Heidelberg.
- [0144] Engebrecht J, Nealson K, Silverman M. 1983. Bacterial bioluminescence: isolation and genetic analysis of functions from Vibrio fischeri. Cell 32: 773-781.
- [0145] Foran, D. R., & Brown, W. M. (1988). Nucleotide sequence of the LuxA and LuxB genes of the bioluminescent marine bacterium Vibrio fischeri, 16(2), 777.
- [0146] Daniel Gietz, R.; Woods, R. A. Transformation of yeast by lithium acetate/single-stranded carrier DNA/polyethylene glycol method. In Methods in Enzymology; Guthrie, C., Fink, G. R., Eds; Academic Press, 2002; Vol. 350, pp. 87-96.
- [0147] Gruhlke, M. C. H., Schlembach, I., Leontiev, R., Uebachs, A., Gollwitzer, P. U. G., Weiss, A., Delaunay, A., Toledano, M., Slusarenko, A. J. (2017). Yap1p, the central regulator of the S. cerevisiae oxidative stress response, is activated by allicin, a natural oxidant and defense substance of garlic. Free Radical Biology and Medicine, 108, 793-802. https://doi.org/10.1016/j.freeradbiomed.2017.05.004
- [0148] Gupta, R. K., Patterson, S. S., Ripp, S., Simpson, M. L., & Sayler, G. S. (2003). Expression of the Photorhabdus luminescens lux genes (luxA, B, C, D, and E) in Saccharomyces cerevisiae. FEMS Yeast Research, 4(3), 305-313.
- [0149] Jansen, G.; Wu, C.; Schade, B.; Thomas, D. Y.; Whiteway, M. Drag&Drop cloning in yeast. Gene 2005, 344, 43-51, doi:10.1016/j.gene.2004.10.016.
- [0150] Minskaia, E., Nicholson, J., & Ryan, M. D. (2013). Optimisation of the foot-and-mouth disease virus 2A co-expression system for biomedical applications. BMC Biotechnology, 13, 1-11. https://doi.org/10.1186/1472-6750-13-67
- [0151] Mumberg, D., Müller, R., & Funk, M. (1995). Yeast vectors for the controlled expression of heterologous proteins in different genetic backgrounds. Gene, 156(1), 119-122. https://doi.org/10.1016/0378-1119(95)00037-7.
- [0152] Pelletier, J., & Sonenberg, N. (1988). Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA. Nature, 334(6180), 320-325. https://doi.org/10.1038/334320a0
- [0153] Xu, T., Young, A., Marr, E., Sayler, G., Ripp, S., & Close, D. (2018). A rapid and reagent-free bioassay for the detection of dioxin-like compounds and other aryl hydrocarbon receptor (AhR) agonists using autobioluminescent yeast. Analytical and Bioanalytical Chemistry, 410(4), 1247-1256. https://doi.org/10.1007/s00216-017-0780-1

Claims

What is claimed is:

1. A nucleic acid comprising a continuous nucleotide sequence containing:

(i) a gene encoding LuxA,

(ii) a gene encoding LuxB,

(iii) a gene encoding LuxC,

(iv) a gene encoding LuxD, and

(v) a gene encoding LuxE,

wherein each of the genes is under the control of a yeast, animal, viral or synthetic promoter heterologous to the respective gene, wherein all of the genes together with the promoter are contained in a single nucleotide sequence in a row, wherein the promoters mediate approximately equal expression levels, wherein each gene is followed by a terminator, and/or the nucleic acid does not contain an internal ribosomal entry site and/or self-cutting peptides between any of genes (i) to (vi).

2. The nucleic acid according to claim 1, wherein the gene encoding LuxA and the gene encoding LuxB are from Photorhabdus luminescens or Vibrio harveyi,

(i) wherein LuxA has an amino acid sequence that is at least 70% identical to SEQ ID NO: 1; and/or

(ii) wherein LuxB has an amino acid sequence that is at least 70%, identical to SEQ ID NO: 2.

3. The nucleic acid according to claim 1, wherein the genes encoding LuxA (i) and LuxB (ii) are present as a gene luxAB encoding the LuxA/LuxB fusion protein and wherein LuxA and LuxB are connected by a linker.

4. The nucleic acid according to claim 1, wherein LuxC, LuxD and LuxE are from P. luminescens (i) wherein LuxC has an amino acid sequence that is at least 70% identical to SEQ ID NO: 3;

(ii) wherein LuxD has an amino acid sequence that is at least 70% identical to SEQ ID NO: 4; and/or

(iii) wherein LuxE has an amino acid sequence that is at least 70% identical to SEQ ID NO: 5.

5. The nucleic acid according to claim 1, wherein the nucleic acid additionally comprises (vi) a gene encoding an NADPH flavin oxidoreductase, wherein said NADPH flavin oxidoreductase is frp, from V. harveyi, wherein the NADPH-flavin oxidoreductase has an amino acid sequence that is at least 70% identical to SEQ ID NO: 6.

6. The nucleic acid according to claim 1, wherein luxA and luxB or the LuxA/LuxB fusion protein are under the control of a regulatable yeast, animal, viral, or synthetic promoter, wherein the regulatable yeast, animal, viral, or synthetic promoter is regulatable by an environmental influence selected from the group consisting of medicaments, drugs, hormones, environmental toxins, bioavailable compounds and physical influences.

7. The nucleic acid according to claim 1, wherein luxC, luxD, luxE and optionally the NADPH-flavin oxidoreductase are constitutively expressed or under the control of a regulatable yeast, animal viral, or synthetic promoter, wherein the yeast, animal, viral, or synthetic promoter of luxC is the TEF2 promoter, the promoter of luxD is the CDC19 promoter, the promoter of luxE is the ENO2 promoter and/or the promoter of the NADPH-flavin oxidoreductase is the PDC1 promoter.

8. A vector comprising the nucleic acid according to claim 1.

9. A host cell comprising the nucleic acid according to claim 1, wherein the host cell is a yeast selected from the group consisting of Komagataella phaffii (Pichia pastoris), Hansenula polymorpha, Trichoderma reesei, Aspergillus niger, Saccharomyces cerevisiae, Kluyveromyces lactis, Yarrowia lipolytica, Pichia methanolica, Candida boidinii, Komagataella spp., Schizosaccharomyces pombe and Blastobotrys adeninivorans.

10. A method of making a host cell, wherein the host cell is a yeast selected from the group consisting of Komagataella phaffii (Pichia pastoris), Hansenula polymorpha, Trichoderma reesei, Aspergillus niger, Saccharomyces cerevisiae, Kluyveromyces lactis, Yarrowia lipolytica, Pichia methanolica, Candida boidinii, Komagataella spp., Schizosaccharomyces pombe and Blastobotrys adeninivorans, said method comprising introducing the nucleic acid according to claim 1 into a host cell.

11. A method for detecting an environmental influence, the method comprising:

(i) Contacting an environmental sample with the host cell according to claim 9;

(ii) Determining the luminescence of the host cell,

wherein luxA and luxB or the LuxA/LuxB fusion protein are optionally under the control of a regulatable promoter that is regulated by the environmental influence and wherein a change in bioluminescence compared to a control sample is indicative of the presence of said environmental influence,

wherein the environmental influence is selected from the group consisting of medicaments, drugs, hormones, environmental toxins, bioavailable compounds, and physical influences.

12. A biosensor for detecting protein-protein interactions comprising a host cell according to claim 9.

13. A vitality sensor for indicating reduced vitality of a host cell comprising a host cell according to claim 9, wherein reduction or loss of bioluminescence is indicative of reduced vitality of the host cell.

14. A kit comprising the nucleic acid according to claim 1.

15. A host cell comprising the vector according to claim 9, wherein the host cell is a yeast selected from the group consisting of Komagataella phaffii (Pichia pastoris), Hansenula polymorpha, Trichoderma reesei, Aspergillus niger, Saccharomyces cerevisiae, Kluyveromyces lactis, Yarrowia lipolytica, Pichia methanolica, Candida boidinii, Komagataella spp., Schizosaccharomyces pombe and Blastobotrys adeninivorans.

16. A method of making a host cell, wherein the host cell is a yeast, preferably a yeast selected from the group consisting of Komagataella phaffii (Pichia pastoris), Hansenula polymorpha, Trichoderma reesei, Aspergillus niger, Saccharomyces cerevisiae, Kluyveromyces lactis, Yarrowia lipolytica, Pichia methanolica, Candida boidinii, Komagataella spp., Schizosaccharomyces pombe and Blastobotrys adeninivorans, preferably Saccharomyces cerevisiae, said method comprising introducing the vector according to claim 8 into a host cell.

17. A nucleic acid comprising a continuous nucleotide sequence containing: